UCSF team engineers B-SYNC CAR-T cells that eliminate diffuse midline glioma in mice
Researchers at UC San Francisco report that a brain-activated version of CAR-T cell therapy wiped out diffuse midline glioma in two mouse models, offering a potential new approach for a childhood brain cancer with almost no survivors.
Scientists at UC San Francisco have developed an engineered immune cell therapy, dubbed B-SYNC CAR-T, designed to remain dormant during circulation and activate only on reaching the brain. In two independent mouse models of diffuse midline glioma (DMG) — an aggressive, treatment-resistant brain tumour that arises predominantly in children and carries a median survival of less than a year — the therapy eliminated tumours in every animal tested, according to a report by ScienceDaily drawing on a press release.
DMG is defined in part by a recurrent histone mutation (H3K27M) and has proved refractory to conventional chemotherapy and radiotherapy. CAR-T cell approaches have been explored previously, but systemic toxicity and the challenges of delivering immune cells across the blood–brain barrier have limited progress. The B-SYNC design is reported to address the activation problem by coupling tumour-antigen recognition to a brain-environment sensor, though the full mechanism is not detailed in the publicly available summary.
The results are preclinical. Mouse models of brain tumours have historically shown limited predictive value for human outcomes, and no human trial data are yet reported. The source material does not name the specific journal or paper; the full peer-reviewed publication should be sought before treating these findings as definitive. For researchers and oncologists working in neuro-oncology and paediatric cancer, the activation-gating strategy represents a conceptually notable engineering approach regardless of whether this particular construct advances.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Diffuse midline glioma is a rare but very serious type of brain tumour that most often affects children and has very few treatment options. Researchers at UC San Francisco have designed a new type of immune cell therapy — called B-SYNC CAR-T — that is built to stay switched off until it reaches the brain, where it then attacks the tumour. In tests in mice, the therapy removed all detectable tumours in every animal tested.
This research is at a very early stage. Results in mice do not always translate to humans, and no trials in people have been reported yet. Scientists will need to do much more testing before knowing whether this approach could one day be used to treat children with this condition.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-11-08Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapy